Our conclusion is supported by parallel evidence in other cancers: In a recent pancreatic cancer study, ZDHHC9 silencing transformed the tumor milieu from “cold” to “hot” and dramatically sensitized tumors to anti-PD-L1 therapy in vivo (32). This evidence concerns the gene ZDHHC9 and pancreatic neoplasm.